HOUSTON – Invectys, Inc., the University of Texas MD Anderson Cancer Center, and the Cell Therapy Manufacturing Center (CTMC), a joint venture between MD Anderson and National Resilience, Inc., today announced a strategic collaboration to jointly develop a reliable, compliant, and scalable process for human leukocyte antigen (HLA)-G targeted chimeric antigen receptor (CAR) T cell therapy for solid tumors.
Download the full article: CTMC_Invectys_MDA_061522_Final.pdf